Bpifrance’s Tempest Therapeutics TPST Stock Holding History

Bpifrance’s Portfolio TPST Stock Details TPST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-2,753	Closed	-$875K	–	6
2020 Q3	$875K	Sell	2,753 -2,779	-50%	-$942K	0.25%	6
2020 Q2	$1.9M	Hold	5,532	–	–	0.47%	6
2020 Q1	$5.7M	Hold	5,532	–	–	1.71%	6
2019 Q4	$7.27M	Hold	5,532	–	–	0.83%	6
2019 Q3	$7.67M	Hold	5,532	–	–	0.83%	6
2019 Q2	$12.5M	Hold	5,532	–	–	1.34%	5
2019 Q1	$16.2M	Hold	5,532	–	–	1.84%	5
2018 Q4	$8.57M	Buy	+5,532	New	+$11.4M	1.1%	6

Other funds holding TPST

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Bpifrance's TPST Position: Q4 2020 in Review

Bpifrance sold out of Tempest Therapeutics (TPST) in Q4 2020, closing a stake of 2,753 shares — an estimated $875K sold.

Bpifrance first reported a position in TPST in Q4 2018 and held it in 8 quarters. The position peaked at $16.2M in Q1 2019. 37 funds tracked by Wall St. Rank hold TPST as of Q4 2020.

Bpifrance reported no remaining Tempest Therapeutics position as of Q4 2020 after selling out during the quarter.
Bpifrance sold 2,753 Tempest Therapeutics shares in Q4 2020, an estimated $875K.
Bpifrance first reported a position in Tempest Therapeutics in Q4 2018 and held it in 8 quarters.
Bpifrance's Tempest Therapeutics position peaked at $16.2M in Q1 2019.
37 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q4 2020.

Based on Bpifrance's 13F filing for Q4 2020, filed 12 Feb 2021.